Involvement of Noradrenergic Transmission in the PVN on CREB Activation, TORC1 Levels, and Pituitary-Adrenal Axis Activity during Morphine Withdrawal by Martín, Fátima et al.
Involvement of Noradrenergic Transmission in the PVN
on CREB Activation, TORC1 Levels, and Pituitary-Adrenal
Axis Activity during Morphine Withdrawal
Fa ´tima Martı ´n
1,2, Cristina Nu ´n ˜ez
1,2, M. Teresa Marı ´n
3, M. Luisa Laorden
1,2, Krisztina J. Kova ´cs
4,M .
Victoria Milane ´s
1,2*
1Group of Cellular and Molecular Pharmacology, Department of Pharmacology, School of Medicine, University of Murcia, Murcia, Spain, 2Instituto Murciano de
Investigacio ´n Biosanitaria (IMIB), Murcia, Spain, 3Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, Granada, Spain,
4Laboratory of Molecular Neuroendocrinology, Institute of Experimental Medicine, Budapest, Hungary
Abstract
Experimental and clinical findings have shown that administration of adrenoceptor antagonists alleviated different aspects
of drug withdrawal and dependence. The present study tested the hypothesis that changes in CREB activation and
phosphorylated TORC1 levels in the hypothalamic paraventricular nucleus (PVN) after naloxone-precipitated morphine
withdrawal as well as the HPA axis activity arises from a1- and/or b-adrenoceptor activation. The effects of morphine
dependence and withdrawal on CREB phosphorylation (pCREB), phosphorylated TORC1 (pTORC1), and HPA axis response
were measured by Western-blot, immunohistochemistry and radioimmunoassay in rats pretreated with prazosin (a1-
adrenoceptor antagonist) or propranolol (b-adrenoceptor antagonist). In addition, the effects of morphine withdrawal on
MHPG (the main NA metabolite at the central nervous system) and NA content and turnover were evaluated by HPLC. We
found an increase in MHPG and NA turnover in morphine-withdrawn rats, which were accompanied by increased pCREB
immunoreactivity and plasma corticosterone concentrations. Levels of the inactive form of TORC1 (pTORC1) were decreased
during withdrawal. Prazosin but not propranolol blocked the rise in pCREB level and the decrease in pTORC1
immunoreactivity. In addition, the HPA axis response to morphine withdrawal was attenuated in prazosin-pretreated rats.
Present results suggest that, during acute morphine withdrawal, NA may control the HPA axis activity through CREB
activation at the PVN level. We concluded that the combined increase in CREB phosphorylation and decrease in pTORC1
levels might represent, in part, two of the mechanisms of CREB activation at the PVN during morphine withdrawal.
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Introduction
Opiate withdrawal is associated with central noradrenergic
neurons hyperactivity, and it has been proposed that noradren-
ergic afferents to the extended amygdala and to the hypothalamic
paraventricular nucleus (PVN) are critically involved in the
aversive properties (such as conditioned place aversion) as well
as in the somatic symptoms of opiate withdrawal (teeth chattering,
piloerection, lacrimation, rinorrhea and ptosis) [1–3]. These
noradrenergic afferents originate in the nucleus of the solitary
tract (NTS) and ventrolateral medulla (VLM) noradrenergic A2
and A1 cell groups [1,4].
Clinical and experimental findings have shown that adminis-
tration of a1- and/or b-adrenoceptor antagonists reduced certain
aspects of drug withdrawal and dependence, such as the negative
emotional status, self administration and relapse [2,5–7]. Further-
more, clonidine, an a2-adrenoceptor agonist, has been reported to
attenuated withdrawal symptoms in humans and animals [8,9]. A
prime candidate for the central actions of the adrenoceptor
antagonists is the PVN, a structure with remarkably dense
noradrenergic innervations [10,11]. Altered neuronal activity has
been found in the PVN after naloxone-induced opiate withdrawal,
as evidenced by increased activation of the immediate early gene
product c-Fos and enhanced hypothalamus-pituitary-adrenocorti-
cal (HPA) axis response (as reflected by plasma levels of
corticosterone, a marker for the HPA axis activity). These
alterations were markedly decreased by systemic adrenoceptor
antagonists [2,12]. Previous works have also shown that lesion of
ascending axons of the ventral noradrenergic bundle markedly
reduced opiate withdrawal-induced place aversion [1]. Further-
more, pretreatment with adrenoceptor antagonists attenuated
heroinselfadministration in rats [13], suggesting that noradrenergic
system may contribute to mechanisms that promote dependence.
On the other hand, morphine dependence exerts long-lasting
effects on gene expression [14,15]. Precipitated morphine
withdrawal has shown several indices of cAMP Response Element
Binding protein (CREB) function within the PVN, including
elevated c-Fos expression in rats [12,16]. It has been proposed that
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and expression of opioid dependence [17,18]. Recently, we found
increased phosphorylated CREB (pCREB) expression within CRF
immunoreactive neurons in the PVN and within tyrosine-
hydroxylase (TH)-positive neurons in the nucleus of the solitary
tract (NTS) in morphine-withdrawn rats, which paralleled
elevation of plasma corticosterone levels [19].
The purpose of the present series of experiments was to test the
hypothesis that CREB activation in the PVN and the enhanced
response of the HPA axis during naloxone-precipitated morphine
withdrawal would arise from the activation of a1- and/or b-
adrenoceptor. Specifically, the effects of prazosin (a1-adrenoceptor
antagonist) and propranolol (b-adrenoceptor antagonist), were
evaluated for their ability to modulate both CREB activation in
the PVN and the pituitary-adrenocortical response to precipitated
morphine withdrawal. Phosphorylation of CREB has been used as
a marker for the activation of CREB-mediated gene transcription.
However, there is recent evidence showing that some extracellular
stimuli that cause CREB phosphorylation fail to induce CREB-
dependent transcription [20]. These findings suggest that there
must be additional CREB co-activators that control the kinetics of
CREB-target gene expression. It led to the discovery of a family of
coactivators called transducers of regulated CREB activity
(TORCs) [21], which facilitate CREB-mediated gene transcription
[22]. TORCs are maintained in an inactive state in the cytoplasm
as a result of phosphorylation. Different stimuli lead to TORC
dephosphorylation and subsequent nuclear accumulation, where-
by it can freely associate with CREB. The second aim of the
present study was to assess the possibility that the activation of the
CREB coactivator, TORC1 in the PVN arises from activation of
a1- and/or b-adrenoceptor.
Results
In accordance with previous findings, Student’s t-test showed
that rats receiving long-term morphine treatment had significantly
lower weight gain (1.6462.61 g; t(76)=6.308; p,0.001; n=42)
than the placebo control group (22.7261.93 g; n=36), which
might be due to the reduced food intake observed during chronic
morphine treatment [23]. The body weight loss after saline or
naloxone injection to placebo-pelleted and morphine-dependent
rats was recorded as a sign of opiate withdrawal. Two-way
ANOVA revealed that chronic pretreatment, acute injection, and
the interaction between chronic pretreatment and acute treatment
had a significant effect on body weight loss [morphine treatment:
F(1,37)=37.60, p,0.0001; naloxone injection: F(1,37)=36.91,
p,0.0001; interaction: F(1,37)=16.31, p=0.0003]. In agreement
with our previous results [24,25], post hoc analysis showed (Table 1)
that naloxone injection to morphine-dependent animals signifi-
cantly increased (p,0.001) body weight loss when measured
60 min after injection compared with the placebo-pelleted group
also receiving naloxone and with the morphine-treated rats
receiving saline. However, administration of naloxone to control
rats resulted in no significant changes in body weight loss,
compared with control rats receiving saline. In animals pre-treated
with prazosin (1 mg/kg i.p.), two-way ANOVA revealed signifi-
cant effects of chronic pretreatment [F(1,26)=106.87; p,0.0001]
and acute drug injection [F(1,26)=8.21; p,0.0081]. There was a
significant (p,0.01) decrease in body weight loss during morphine
withdrawal in animals receiving prazosin 20 min before naloxone
injection compared with morphine-withdrawn rats receiving
vehicle. In animals pretreated with propranolol (3 mg/kg i.p.),
two-way ANOVA showed a significant effect of chronic
pretreatment [F(1,25)=66.53; p,0.0001]. In contrast to prazosin,
post hoc test revealed that pretreatment with propranolol did not
significantly attenuate the increase in body weight loss in
morphine-withdrawn animals compared with morphine-with-
drawn rats receiving vehicle instead of propranolol. Neither
prazosin nor propranolol modified the weight loss in placebo-
pretreated rats compared to placebo-treated rats receiving vehicle.
Effects of naloxone-induced morphine withdrawal on NA
and MHPG levels and NA turnover in the PVN
Fig. 1 summarizes the changes in NA content, 3-Methoxy-4-
hydroxyphenylglycol (MHPG; the metabolite of NA at the central
nervous system) production and NA turnover (as estimated by the
ratio MHPG/NA) after injection of naloxone to control and
morphine-dependent rats. The overall ANOVA on NA content in
the PVN revealed the main effects of acute treatment
[F(1,31)=10.25; p=0.0032] and a significant interaction between
pretreatment and acute treatment [F(1,31)=10.49; p=0.0029].
Post hoc analysis indicated that groups rendered dependent on
morphine and injected with saline showed significantly (p,0.01)
higher levels of NA than the placebo-pelleted groups also injected
with saline (Fig. 1A). By contrast, morphine dependent rats
receiving naloxone showed a significant (p,0.001) decrease in NA
levels 60 min after naloxone injection. The ANOVA for MHPG
production showed a significant effect of chronic pretreatment
[F(1,28)=13.61; p=0.0010]. Post hoc analysis showed that the
MHPG levels increased significantly (p,0.01) in the naloxone-
precipitated morphine withdrawal group, as compared with the
placebo-treated group injected with naloxone and with the
morphine-dependent rats receiving saline instead naloxone
(Fig. 1B). Results for the two-way ANOVA for NA turnover (as
revealed by MHPG/NA ratio) in the PVN showed a significant
effect of chronic pretreatment [F(1,30)=14.03; p=0.0008], and
significant interaction between pretreatment and acute treatment
[F(1,30)=12.53; p=0.0013]. As shown in Fig. 1C, rats rendered
dependent on morphine and injected with naloxone showed a
Table 1. Effects of adrenoceptor blockade on body weight
loss during morphine withdrawal.
Treatment Mean (g) ± S.E.M.
pla+sal 0.261.3
pla+nx 2.660.3
mor+sal 2.660.3
mor+nx 14.561.2***
+++
pla+veh+nx 3.061.3
pla+praz+nx 1.460.3
mor+veh+nx 15.861.1
mor+praz+nx 11.160.9
##
pla+veh+nx 2.461.0
pla+prop+nx 4.760.7
mor+veh+nx 15.861.5
mor+prop+nx 13.261.6
Rats were treated with pellets of placebo (pla) or morphine (mor) to induce
depencence and withdrawal precipitated by naloxone (nx). Other groups of rats
received vehicle (veh), prazosin (praz) or propranolol (prop). The weight loss
was checked immediately before and 60 min after saline (sal) and naloxone
injection. Data show the means 6 SEM.
***p,0.001 vs. pla+nx;
+++p,0.001 vs. mor+sal;
##p,0.01 vs. mor+veh+nx.
doi:10.1371/journal.pone.0031119.t001
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group injected with naloxone (p,0.001) and than the morphine-
pelleted group receiving saline instead naloxone (p,0.001).
Effects of adrenergic antagonists on morphine
withdrawal-induced CREB phosphorylation in the PVN
as determined by Western blot and
immunohistochemistry
In previous studies, western blot analysis revealed strong
activation (phosphorylation) of CREB in the PVN after naloxone
injection to morphine-dependent rats, which was dependent on
protein kinase C activation [19]. In the present work we examined
whether noradrenergic neurotransmission is necessary for the
morphine withdrawal-induced CREB phosphorylation. Two-way
ANOVA for rats pretreated with the selective a1-adrenoceptor
antagonist, prazosin revealed that acute prazosin administration
[F(1,22)=23.61; p,0.0001] and the interaction between mor-
phine treatment and prazosin injection [F(1,22)=13.81;
p=0.0012] had a significant effect on pCREB immunoreactivity
in the PVN. As shown in Fig. 2A, Newman-Keuls post hoc test
shows that naloxone injection to morphine-dependent rats
pretreated with vehicle produced a significant (p,0.01) increase
in pCREB levels compared with the placebo-pelleted group also
receiving naloxone, which was blocked (p,0.001) in rats
pretreated with prazosin 20 min prior naloxone. The results were
confirmed by immunohistochemical procedures. As shown in
Fig. 2B, high levels of pCREB immunoreactivity were observed in
the PVN 60 min after naloxone injection to morphine-dependent
rats, whereas the PVN from rats pretreated with prazosin showed
discrete staining for pCREB (Fig. 2C). According to the Western-
blot analysis, there was a decrease (t(8)=3.035; p,0.05) in
pCREB immunoreactivity 60 min after naloxone administration
to morphine-dependent rats pretreated with prazosin (Fig. 3D).
Two-way ANOVA for rats pretreated with the b-adrenoceptor
antagonist, propranolol revealed significant effect of pretreatment
[F(1,22)=26.44; p,0.0001] on pCREB immunoreactivity in the
PVN. Newman-Keuls post hoc test shows that administration of
propranolol 20 min prior naloxone injection produced a similar
increase (p,0.01) in pCREB levels than that seen in morphine
dependent rats pretreated with vehicle instead propranolol
(Fig. 3A). These results were also confirmed by immunohisto-
chemical procedures. As shown in Fig. 3B, C, the PVN from rats
pretreated with propranolol shows similar staining for pCREB
than the PVN from rats receiving vehicle instead propranolol. No
significant differences (t(8)=1.060) were seen between the
morphine-dependent rats receiving vehicle plus naloxone and
those injected with propranolol plus naloxone (Fig. 3D).
Induction of CREB phosphorylation in CRF-positive
neurons in the PVN is attenuated by prazosin
To explore the specificity of the decrease of pCREB levels
observed in the parvocellular part of the PVN during morphine
withdrawal in animals pretreated with prazosin, sections from
different treatment were immunohistochemically double-labeled
for pCREB and CRF (Figure 4 A–C). ANOVA revealed
significant differences in the number of CRF neurons expressing
pCREB in rats pretreated with prazosin [F(2,14)=21,69;
p,0.001]. As shown in Figure 4D (left panel), post hoc comparisons
showed a significant (p,0.01) decrease in the number of CRF
neurons containing pCREB after naloxone-induced morphine
withdrawal in prazosin-pretreated rats compared with those
receiving vehicle instead of prazosin. Additionally, ANOVA also
revealed significant differences [F(2,14)=19,28; p,0.001] in CRF
immunoreactivity in rats pretreated with prazosin. As shown in
Figure 4D (right panel), there was a significant (p,0.01) decrease
in the total number of CRF neurons after naloxone-induced
morphine withdrawal in prazosin-pretreated rats.
Figure 1. Effects of naloxone-induced morphine withdrawal on
NA and MHPG levels at the PVN and on NA turnover (as
estimated by the MHPG/NA ratio. Morphine withdrawal increased
MHPG production and NA turnover. Data represent the mean 6 SEM
60 min after naloxone injection to control pellets- or morphine-treated
rats. **p,0.01; ***p,0.001 vs. control pellets (placebo)+naloxone;
+p,0.05,
+++p,0.001 vs. morphine-treated rats+saline;
## p,0.01 vs.
placebo-treated rats+saline.
doi:10.1371/journal.pone.0031119.g001
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analysis and representative immunoblots (A) of pCREB in the PVN tissue isolated from placebo or morphine-dependent rats pretreated with prazosin
before saline or naloxone injection to control and to morphine-dependent rats. Post hoc analysis revealed that the increase in CREB phosphorylation
during morphine withdrawal was blocked by prazosin (1 mg/kg i.p.). Each bar represents mean 6 SEM (% of controls); p: placebo pellets; m:
morphine pellets; veh: vehicle; n: naloxone; praz: prazosin. **p,0.01 vs control pellets (placebo)+vehicle+naloxone;
+++p,0.001 vs. morphine-treated
rats+ to control and to morphine-dependent rats. vehicle+naloxone. PVN was also processed for pCREB immunohistochemistry. (B, C) represents
immunohistochemical detection of pCREB in the PVN from morphine-treated rats receiving vehicle and naloxone (B) or prazosin plus naloxone (C).
3V: third ventricle. Scale bar: 100 mm. D: quantitative analysis of pCREB immunoreactivity the PVN. Data correspond to mean 6 SEM. Post hoc analysis
revealed a significant decrease in pCREB immunoreactivity in prazosin-pretreated rats. *p,0.05 versus morphine+vehicle+naloxone.
doi:10.1371/journal.pone.0031119.g002
Figure 3. Morphine withdrawal-induced CREB activation in the PVN is not dependent on b-adrenoceptor stimulation. Quantitative
analysis and representative immunoblots (A) of pCREB in the PVN tissue isolated from placebo or morphine-dependent rats pretreated with
propranolol before saline or naloxone injection to control and to morphine-dependent rats. Post hoc analysis revealed that the increase in CREB
phosphorylation during morphine withdrawal was not modified by propranolol (3 mg/kg i.p.). Each bar represents mean 6 SEM (% of controls); p:
placebo pellets; m: morphine pellets; veh: vehicle; n: naloxone; prop: propranolol. **p,0.01 vs. control pellets (placebo)+naloxone;
++p,0.01 vs.
placebo-treated rats+propranolol+naloxone. PVN was also processed for pCREB immunohistochemistry. (B, C) represents immunohistochemical
detection of pCREB in the PVN from morphine-treated rats receiving vehicle and naloxone (B) or propranolol plus naloxone (C). 3V: third ventricle.
Scale bar: 100 mm. D: quantitative analysis of pCREB immunoreactivity the PVN. Data correspond to mean 6 SEM. Post hoc analysis revealed no
significant effects of propranolol pretreatment on pCREB immunoreactivity.
doi:10.1371/journal.pone.0031119.g003
NA and CREB during Morphine Withdrawal
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morphine withdrawal
Two-way ANOVA revealed a significant effect of acute
injection [F(1,19)=11.89; p=0.0027], and an interaction between
chronic pretreatment and acute treatment [F(1,19)=7.87;
p=0.0113] on pTORC1 levels at the PVN. As shown in Fig. 5,
Western blot analysis revealed a significant (p,0.01) decrease for
pTORC1 immunoreactivity in morphine-withdrawn rats com-
pared with the control group receiving naloxone. To determine
the ability of the a1-adrenoceptor blockade on pTORC1
expression, control- and morphine- treated rats were pretreated
with prazosin 20 min before saline or naloxone injection. Post hoc
analysis showed that prazosin reverted (p,0.001) the decreased
pTORC1 levels observed during morphine withdrawal.
Effects of adrenergic antagonists on morphine
withdrawal-induced HPA axis activation
We measured plasma corticosterone concentrations (as HPA
axis activation marker) in blood samples obtained from morphine-
dependent or control rats 60 min after injection of saline or
naloxone. Two-way ANOVA for corticosterone revealed a
significant effect of chronic pretreatment [F(1,16)=111.58;
p,0.0001], significant effect of acute drug administration
[F(1,16)=117.24; p,0.0001] and significant interaction between
acute treatment and chronic pretreatment [F(1,16)=127.58;
p,0.0001]. As shown in Fig. 6A, in morphine-withdrawn rats
plasma corticosterone levels increased significantly (p,0.001)
compared with those observed in the placebo group also receiving
naloxone and the morphine dependent rats receiving saline. Two-
wayANOVAforcorticosteroneinratsreceivingprazosinrevealeda
significant effect of acute injection [F(1,17)=106.56; p,0.0001],
chronic pretreatment [F(1,17)=108.78; p=0.0001], and significant
interaction between acute and chronic treatment [F(1,17)=83.10;
p,0.0001]. As shown in Fig. 6B, although morphine-withdrawn
rats pretreated with prazosin showed elevated (p,0.001) plasma
corticosterone levels compared with its control group, a reduction
(p,0.01; Dunnet test) in corticosterone levels was observed in
morphine pretreated rats injected with prazosin before naloxone
compared with morphine-withdrawn rats. Two-way ANOVA for
corticosterone in rats receiving propranolol revealed a significant
effect of acute injection [F(1,17)=165.49; p,0.0001], chronic
pretreatment [F(1,17)=160.72; p=0.0001], and significant inter-
action between acute and chronic pretreatment [F(1,17)=164.21;
p,0.0001]. As shown in Fig. 6C, in morphine-withdrawn rats
administered propranolol, the plasma corticosterone levels in-
creased significantly (p,0.001). By contrast to prazosin pretreat-
ment, pretreatment with propranolol did not modify the morphine
Figure 4. Increased pCREB into CRF neurons after naloxone-induced morphine withdrawal is a-1 adrenoceptor dependent. PVN
tissue isolated from placebo or morphine-dependent rats pretreated with vehicle or prazosin before naloxone injection was processed for pCREB and
CRF double-label immunohistochemistry. Top panels (A–C) represent immunohistochemical detection of pCREB into CRF neurons after the different
treatments. Low and high magnifications images show pCREB-positive (blue-black)/CRF-positive (brown) neurons in the PVN. Scale bar: 100 mm (low
magnification); 20 mm (high magnification). 3V, third ventricle. Bottom panels (D) show quantitative analysis of pCREB-positive/CRF-positive and total
CRF-positive (with or without pCREB) neurons in the PVN. Data shown are means 6 SEM. Post hoc test revealed a higher number of pCREB-positive
nuclei in CRF immunoreactive neurons after naloxone-induced morphine withdrawal. This increase was antagonized in prazosin-pretreated rats. The
increase in number of CRF-positive neurons during morphine withdrawal was also blocked by prazosin. ***p,0.001 versus placebo (pla)+vehicle
(veh)+naloxone (nx);
++p,0.01 versus mor+veh+nx.
doi:10.1371/journal.pone.0031119.g004
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prazosin nor propranolol induced any significant modification in
plasma levels of corticosterone in control rats receiving saline or
naloxone or in morphine-pretreated rats receiving saline.
Discussion
For many years, studies have focused on the role of
dopaminergic reward system in drug abuse. However, although
the role of NA in stress is well known, its involvement in drug
addiction has received less attention. It has been demonstrated
that opiate withdrawal results in marked activity of central
noradrenergic neurons [1,26]. Thus, several biochemical and
electrophysiological changes induced by opiate abstinence have
been reported, consisting of an increase in firing rate response by
application of opiate antagonists after chronic morphine treatment
[27,28]. Furthermore, NA caused a marked increase in the
frequency of postsynaptic potentials of the parvocellular neurons of
the PVN [29]. There is also evidence that increased NA is involved
in various aspects of the withdrawal response [23,26].
The PVN, a component of the HPA stress axis, has a high
density of noradrenergic inputs [1,30] and is anatomically
connected with other brain areas implicated in drug abuse, such
as the extended amygdala (the brain stress system) and the NTS-
A2. We therefore hypothesized that the HPA axis may be an
important site for the actions of NA during withdrawal. Previous
studies from our group indicate that NA turnover is increased in
the PVN 30 min after naloxone administration to morphine-
dependent rats [2]. Present findings show that morphine
withdrawal also enhances noradrenergic activity in the PVN at
60 min time-point, as revealed by increased MHPG production
and NA turnover in this nucleus, as Fig. 1 depicts. These effects
have been shown to be accompanied by increased CRF hnRNA,
TH mRNA expression and tyrosine-hydroxylase (TH) enzymatic
activity in the PVN and are induced via a mechanism involving
phosphorylation of TH at Ser31 [2,23]. The present study was
focused on the impact of noradrenergic modulation in the context
of withdrawal-induced CREB phosphorylation and HPA axis
activation that is observed in morphine-withdrawn rats.
As reported recently [19], the data depicted in Fig. 2 indicate
that naloxone-induced morphine withdrawal produced robust
CREB activation in the hypothalamic PVN. These effects of
morphine abstinence are mediated through the activation
(phosphorylation) of CREB, but not through the up-regulation
of its expression in the PVN, as previously shown by Martı ´n et al.
[18,19]. CREB regulates the transcription of over 10,000 genes,
including those implicated in stress and addiction, such as CRF
[31]. The present work showed that the increase in pCREB
immunoreactivity co-localized with CRF neurons of the parvo-
cellular part of the PVN (Fig. 4), consistent with the morphine
withdrawal-induced the transcriptional regulation of CRF in the
PVN. Thus, using probes complementary to intronic sequences of
the gene encoding CRF in the parvocellular neurosecretory
neurons of the PVN, we had found robust increases in the
precursor mRNA (hnRNA) for CRF in morphine-dependent rats
during naloxone-precipitated morphine withdrawal [16]. In
addition, previous findings showed that the induction of c-Fos
expression that occurs during morphine withdrawal occurs
predominantly in hnRNA CRF-expressing neurons of the
parvocellular part of the PVN, consistent with transcriptional
regulation of CRF neurons by morphine withdrawal [16]. Taken
together, present results might suggest that activation of CREB
could contribute to the increased CRF gene-transcription during
morphine withdrawal. Supporting this hypothesis are previous
findings indicating that CREB is a potent activator of CRF
transcription [20,32]. Furthermore, Itoi et al. [31] showed that
injection of antisense oligodeoxynucleotides to CREB blocked the
increase in CRF mRNA caused by stress and drug exposure [33].
According to these findings, in the present study we have shown
Figure 5. Noradrenergic activity is required for morphine
withdrawal-induced TORC1 activation in the hypothalamic
PVN. Quantitative analysis and representative immunoblots of
phosphorylated TORC 1 in the PVN tissue isolated from placebo or
morphine-dependent rats pretreated with vehicle or prazosin before
saline or naloxone injection to control and to morphine-dependent rats.
Post hoc analysis revealed that the decrease in TORC phosphorylation
induced by morphine withdrawal was reversed by prazosin. Each bar
represents mean 6 SEM (% of controls); p: placebo pellets; m: morphine
pellets; veh: vehicle; n: naloxone; praz: prazosin. **p,0.01 vs. control
pellets (placebo)+vehicle+naloxone;
+++p,0.001 vs. morphine-treated
rats+vehicle+naloxone.
doi:10.1371/journal.pone.0031119.g005
Figure 6. Hypothalamus-pituitary-adrenal (HPA) axis activation
during morphine withdrawal is attenuated by a1- but not b-
adrenoceptor blockade. Placebo and morphine-dependent rats
were pretreated with prazosin or propranolol and plasma levels of
corticosterone (a marker of HPA axis activity) were determined 60 min
after naloxone injection. Praz: prazosin; prop; propranolol; sal: saline; nx:
naloxone. Each bar represents mean 6 SEM. Post hoc analysis revealed
a significant increase in plasma corticosterone concentration after
naloxone-induced morphine withdrawal, which was attenuated in
prazosin- but not in propranolol-pretreated rats. ***p,0.001 versus
placebo+naloxone;
+++p,0.001 versus morphine+saline;
&&&p,0.001
versus placebo+prazosin+naloxone;
$$$p,0.001 versus morphine+pra-
zosin+saline;
##p,0.01 versus morphine+naloxone; @@@p,0.001
versus placebo+propranolol+naloxone;
%%%p,0.001 versus morphine+
propranolol+saline.
doi:10.1371/journal.pone.0031119.g006
NA and CREB during Morphine Withdrawal
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PVN, as Fig. 4 depicts. The increase in number of CRF-positive
neurons could be the results from an increase in the synthesis of
the peptide then an increase in the peptide content in the CRF
perikaria of the PVN. Although indirectly, all these results might
suggest that activation of CREB could contribute to increased
transcription of CRF gene during morphine withdrawal.
In the present study, the effects of a1- (prazosin) and b-
(propranolol) adrenoceptor antagonists were evaluated for their
ability to modify CREB phosphorylation, CRF immunoreactivity
and corticosterone release in morphine-dependent rats. Present
findings clearly show that, at the PVN level, only the a1-
adrenoceptor can stimulate CREB phosphorylation, since prazosin
but not propranolol significantly decreased morphine withdrawal-
induced CREB phosphorylation (Figs. 2, 3). Furthermore, norad-
renergic a1 receptor blockade by prazosin significantly attenuated
the morphine withdrawal-induced CREB activation into CRF-
positive neurons (Fig. 4). We showed that this response was
associated with a reduction of both CRF-containing neurons and
corticosterone release,asFigs.4 and 6depict.Thesefindingssuggest
that the ability of morphine withdrawal to stimulate CREB
activation and the stress axis activity is under control of
noradrenergic system via a1-adrenoceptor stimulation. This is in
accordance with several reports describing the modulatory action of
the noradrenergic system on the hypothalamic stress axis. Indeed,
NA neurons arising from the NTS-A2 provide excitatory inputs to
the CRF neurons in the PVN, and activation of these neurons
during precipitated morphine withdrawal or during stress was
blocked by prazosin [12,34]. Since NA was found to stimulate
CREB phosphorylation [35,36], and considering that CREB
phosphorylation is critical for CRF transcription, it is reasonable
to hypothesize that inhibition of morphine withdrawal-induced
CREB activation by prazosin may be responsible for the inhibitory
effect of this adrenoceptor antagonist on HPA axis activity, whereas
the b-adrenoceptor seems not to be involved in those actions.
Electrical stimulation of the ventral ascending noradrenergic
bundle and intracerebroventricular injection of NA, increase
pituitary-portal plasma levels of CRF [37]. Moreover, NA
injection directly into the PVN has a similar effect, which was
prevented by a1 but not b-adrenoceptor antagonists [38]. Taken
together, these results would suggest a positive correlation between
noradrenergic terminals innervating the PVN and HPA axis
activity. In addition to the proposed direct effects of NA on
adrenoceptor located on the CRF neurons, it has been shown that
NA can also influence the activity of the HPA axis through
activation of adrenergic receptors located on the bed nucleus of
the stria terminalis (BNST; [39]) in response to stress. Daftary et al.
[29] reported that CRF release may be also evoked through
intrahypothalamic glutamatergic interneurons expressing a1-
adrenoceptors, indicating the complexity of the interaction
between noradrenergic system and CRF neurons.
CREB is classically considered to be the mediator of c-AMP/
PKA-mediated effects. According to the conventional model, cAMP
activates PKA, leading to sequential phosphorylation of CREB,
binding of phospho-CREB to the c-AMP-Response Element (CRE)
inthe CRF promoter and activation oftranscription [40]. According
to our results, it has been shown that noradrenergic neurons
stimulate CRF cells via a1-adrenoceptors and hence the HPA axis
[41–43]. The a1 receptor is coupled to phospholipase C/PKC signal
transduction pathway. Thus, it is possible that stimulation of
phospholipids signaling by NA would lead to CREB phosphoryla-
tion and subsequent activation of the CRF neurons in the PVN from
morphine-withdrawn rats. Supporting this possibility, PKC antag-
onists prevented the observed morphine withdrawal-induced CREB
phosphorylation into CRF neurons in the rat PVN [19]. In addition,
activation of calcium phospholipids-dependent pathways by the
phorbol ester PMA also activated CREB phosphorylation in
hypothalamic neurons [20]. According to all these findings, the
results of the present study strongly suggest the relevance of a1-
adrenoceptor in mediating the CREB phosphorylation that was seen
after naloxone-induced morphine withdrawal. In addition, our
findings support a facilitatory influence of NA on morphine
withdrawal-induced HPA activation. However, since prazosin
attenuated, but did not block the HPA axis response to morphine
withdrawal, others receptor systems may be activated in addition to
a1-adrenoceptors, such as CRF2 receptors and orexin receptors
[44,45]. An additional explanation for the present findings is that,
although CRF isthought to be the majorsecretagogue instimulating
ACTH secretion, AVP and other factors also play a role [46,47].
Previous studies suggest that the phosphorylation site of CREB is
a convergence point for multiple kinases and acts as a molecular
switch for controlling gene activation kinetics [48]. CREB activity
can also be regulated by the new family of transcriptional
coactivators, TORCs [49]. It has been recently shown that CREB
is essential but not sufficient for activation of CRF transcription,
suggestingthattranslocationofTORCstothenucleusisrequired for
CRF transcription by acting as a CREB coactivator [50]. TORCs
phosphorylation by specific kinases increases its affinity with the
scaffolding protein 14-3-3, thus preventing nuclear translocation
[51]. The present study focused on investigating the effects of
morphine withdrawal and adrenoceptor blockade on phosphorylat-
ed TORC1 (pTORC1) levels. Our results show that morphine
withdrawal produced a decrease of pTORC1, the inactive form of
this CREB coactivator (Fig. 5), which suggests that TORC1 was
dephosphorylated (activated) in response to morphine abstinence.
The mechanism regulating TORCs activation is under current
investigation [50]. Our findings also show that pretreatment with
prazosin antagonized the morphine withdrawal-induced decreased
of pTORC1 levels in the PVN. Therefore, all this evidence might
indicate that morphine withdrawal-induced activation of TORC1
would requirethe activationofa1- adrenoceptor,whichsuggeststhat
phospholipids-dependent pathways might be involved in TORC1
activation, providing a mechanism by which morphine withdrawal
and a1- agonist induce a stimulatory effect on CRF neurons.
It has been shown that the use of ligands targeting noradrenergic
receptor subtypes can attenuate both the physical and motivational
components of enhanced drug ingestion that has been observed in
opiate-, alcohol-, and nicotine-dependent animals and humans
[6,7,13,52,53]. The PVN appears to be a very important site of
action for the a1-ligand-mediated effects on feeding [13]. The
observation that prazosin but not propranolol attenuated the
reduction in weight loss during morphine withdrawal would
indicates that noradrenergic pathways may participate in a subset
of somatic withdrawal signs through stimulation of a1-adrenoceptor
subtype, as has been previously shown [2].
In summary, our results suggest that NA and a1-adrenoceptors
may control the HPA axis activity through CREB activation at the
PVN during acute morphine withdrawal. The combination of
CREB phosphorylation and in pTORC1 dephosphorylation
(activation) might represent, in part, two of the mechanisms of
CREB activation at the PVN during morphine withdrawal.
Materials and Methods
Animals
Male Sprague-Dawley rats (220–240 g; Harlan, Barcelona,
Spain) were housed two-to-three per cage in a room with
controlled temperature (2262uC) and humidity (50610%), with
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12-h light-dark cycle for 7 days before the beginning of the
experiments. All surgical and experimental procedures were
performed in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC) and the
local Committees for animal research (REGA ES300305440012).
The study was approved by the University of Murcia bioethics
committee (RD 1201/2005) and Ministerio de Ciencia y
Tecnologı ´a (SAF2009-07178), Spain.
Drug treatment and experimental procedure
Groups of rats were rendered dependent on morphine by s.c.
implantation of morphine base pellets (75 mg), one on day 1, two
on day 3 and three on day 5, under light ether anesthesia. Control
animals were implanted with placebo pellets containing lactose
instead of morphine on the same time schedule. This morphine
treatment paradigm has been shown to produce profound states of
tolerance and dependence and to result in characteristic
biochemical adaptations within the paraventricular nucleus and
behavioral alterations [23,54]. On day 8, when rats were
morphine dependent, animals were injected i.p. with vehicle,
prazosin (1 mg/kg) or propranolol (3 mg/kg) and 20 min later
received saline s.c. or naloxone (2 mg/kg s.c.). On the basis of our
initial experiments of prazosin-induced inhibition of behavioral
signs of morphine withdrawal and HPA axis activity [2,12] 1 mg/
kg dose of prazosin was chosen for our experiments. Dose of
propranolol was selected on the basis of previous findings [12].
The weight gain of the rats was checked during treatment to
ensure that the morphine was liberated correctly from the pellets
because it is known that chronic morphine treatment induces a
decrease in body weight gain due to lower caloric intake [55]. In
addition, the day of experiment weight loss was determined as the
difference between the weight determined immediately before
saline or naloxone injection and a second determination made
60 min later, immediately before killing.
Western blot analysis
Sixty min after administration of naloxone or saline, rats were
killed by decapitation. The hypothalamic tissue containing the
PVN was dissected according to the technique of Palkovits [56].
PVN samples were placed in homogenization buffer [23],
homogenized and sonicated for 30 s before centrifugation at
6,0006g for 10 min at 4uC. Samples containing 40 mg of protein
were loaded on a 10% SDS/polyacrylamide gel, electrophoresed
and transferred onto polyvinylidene difluoride (PVDF) membranes
(Millipore, Bedford, MA, USA). Western analysis was performed
with the following primary antibodies: 1:750 polyclonal anti-
phospho CREB-123-136 (pCREB; Millipore, Temecula, CA);
1:375 polyclonal anti-phospho-TORC1 (pTORC1; Cell Signal-
ing); 1:5000 polyclonal anti-a-tubulin; and 1:1000 polyclonal b-
actin (Cell Signaling). After extensive washing with TBST, the
membranes were incubated with peroxidase-labeled secondary
antibodies. We used a-tubulin or b-actin (depending on the
molecular weight of the protein measured) as our loading controls
for all the experiments. Before re-probing, blots were stripped by
incubation with stripping buffer (glycine 25 mM and SDS 1%,
pH 2) for 1 h at 37uC.
Blots were subsequently reblocked and probed with anti a-
tubulin or b-actin. Quantification of immunoreactivity corre-
sponding to pCREB (43 kDa), pTORC1 (82 kDa), a-tubulin
(52 kDa) and b-actin (45 kDa) bands was carried out by
densitometry. The integrated optical density of the bands was
corrected by subtraction of the background values. The ratios of
pCREB/a-tubulin and PTORC1/b-actin were calculated and
expressed as a percentage of the average of controls in each blot.
Immunohistochemical detection of pCREB
Sixty min after naloxone or saline injections, rats were deeply
anesthetized with pentobarbital (100 mg/kg ip) and quickly
perfused through the ascending aorta with saline followed by
ice-cold fixative. Brains were post-fixed in the fixative for 3 h and
then placed in PBS containing 10% sucrose overnight. Series of
30 mm frontal sections were cut on freezing microtome, collected
in cryoprotectant and stored at 220uC until processing. After
blocking with H2O2 and normal goat serum, sections were then
incubated for 60 h at 4uC with a rabbit anti-pCREB antibody
(Upstate; 1:750). This was followed by application of a biotinylated
anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA), and
then with the avidin–biotin complex. Visualization of the antigen–
antibody reaction sites was performed using 3, 39-diaminobenzi-
dine (DAB, Sigma). Sections were mounted onto chrome-alumn
gelatine coated slides, dehydrated through graded alcohols,
cleared in xylene and cover slipped with dibutylphtalate (DPX).
Double-labeling immunohistochemistry of pCREB-
immunoreactive nuclei and CRF-positive neurons
For pCREB and CRF double-label immunohistochemistry,
tissue sections from each rat in each treatment group were
processed as follows: pCREB was developed with DAB intensified
with nickel, and CRF revealed with DAB. pCREB immunohis-
tochemistry was performed as described above, and pCREB
antibody-peroxidase complex was visualized by using a mixture of
NiSO4.6H2O (33.2 mg/ml), DAB (0.033%) and 0.014% H2O2 in
0.175 M sodium acetate solution (pH 7.5). Sections were then
incubated for 60 h at 4uC with rabbit anti-CRF antibody (1:1000
in PBS containing 2% goat serum and 0.5% Triton-X-100; a
generous gift from Wylie Vale, The Salk Institute, La Jolla, CA,
USA). A biotinylated anti-rabbit IgG (diluted 1:200) for 1 h was
used as a secondary antibody. The CRF antibody-peroxidase
complex was stained in 0.033% DAB and 0.014% H2O2 in
0.05 M Tris-HCl buffer.
Quantification of pCREB immunoreactivity
pCREB immunostaining within section of the PVN was
quantified bilaterally for each rat and for all treatment groups
by an observer blinded to the treatment protocol. The density of
pCREB-like immunoreactivity was determined using a computer-
assisted image analysis system (QWIN, Leica, Madrid, Spain).
This system consists of a light microscope (DM4000B; Leica)
connected to a video camera (DFC290, Leica) and the image
analysis computer.
Quantification of pCREB-positive/CRF-positive neurons
pCREB-positive CRF cells were identified as cells with brown
cytosolic deposits for CRF-positive staining and blue/dark nuclear
staining for pCREB. A square field (195 mm) was superimposed
upon captured image to use as reference area. The number of
double-labeled pCREB neurons observed bilaterally was counted
in three to four sections from each animal in the PVN. The total
number of CRF cells (with or without a visible nucleus) was also
counted.
HPLC
NA and its metabolite in the central nervous system, MHPG,
were determined by HPLC with electrochemical detection as
described previously [57], frozen in liquid nitrogen, weighed,
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and the supernatants taken for analysis and filtered through
0.22 mm GV (Millipore). Ten mL of each sample were injected
into a 5-mm C18 reversed-phase column (Waters, Milford, MA,
USA) through a Rheodyne syringe loading injector (Waters).
Electrochemical detection was accomplished with an electrochem-
ical detector (Waters 2465). NA and MHPG were quantified by
reference to calibration curves run at the beginning and the end of
each series of assays. The content of NA and MHPG in the PVN
was expressed as ng?g
21 wet weight of tissue. The NA turnover
was determined as the NA ratio, which was calculated as: NA
ratio=MHPG/NA.
Radioimmunoassay
Sixty min after saline or naloxone injection, rats were
decapitated. Plasma levels of corticosterone were measured by
commercially available kits for rats (
125I-corticosterone RIA; MP
Biomedicals, Orangeburg, NY). The sensitivity of the assay was
7.7 ng.mL
21.
Materials
Pellets of morphine (75 mg morphine base/pellet; Alcaliber
Labs., Madrid, Spain) or lactose (placebo) were prepared by the
Department of Pharmacy and Pharmaceutics Technology (School
of Pharmacy, Granada, Spain); naloxone HCl, prazosin HCl and
DL-propranolol HCl were purchased from Sigma Chemical Co.
(St Louis, MO). Naloxone HCl and propranolol were dissolved in
sterile 0.9% NaCl (saline); prazosin was dissolved in sterile distilled
water and administered in volumes of 0.1 ml/100 g body weight.
Phosphatase inhibitor Cocktail Set (Calbiochem, Germany);
protease inhibitors (Boehringer Mannheim, Germany). HPLC
reagents were purchased from Sigma.
Statistical analysis
Data are presented as mean 6 S.E.M. Data were analyzed
using one- or two-way analysis of variance (ANOVA) followed by
a post hoc Newman–Keuls test. Student’s t-test was used when
comparisons were restricted to two experimental groups. Differ-
ences with a P-value ,0.05 were considered significant.
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